Objective To explore the clinical efficacy of early micro-porous surgery in the treatment of patients with encephaledema after small-and moderate-volume basal ganglia hemorrhage and its influence on serum inflammatory factors.Methods A total of 104 patients with small-and moderate-volume basal ganglia hemorrhage were randomly divided into control group and observation group,52 cases in each group.Control group was treated with conventional treatment,while observation group was treated with early micro-porous surgery.The volume of encephaledema and clearance time of hematoma 3 d and 14 d after treatment were observed in both groups.The levels of serum interleukin-6 (IL-6),IL-13 and tumor necrosis factors-α (TNF-o) were detected before treatment and 3 d after treatment in both groups.National Institutes of Health Stroke Scale (NIHSS) and Activities of Daily Life Function Assessment Scale Barthel index (BI) were used before and 3 weeks after treatment to evaluate patients' neurological function.Results The 3 d and 14 d after treatment,observation group was significantly smaller in volume of encephaledema (P ＜ 0.05) and shorter in clearance time of hematoma (P ＜0.01) when compared with control group.Three days after treatment,levels of serum IL-6,IL-1 β and TNF-α decreased significantly in both groups,which decreased more significantly in observation group than in control group (P ＜0.05 or P ＜0.01).Three weeks after treatment,NIHSS score decreased significantly while BI increased significantly in both groups,which improved more significantly in observation group than in control group (P ＜ 0.05).Conclusion Early micro-porous surgery can significantly relieve the severity of encephaledema after intracerebral hemorrhage,and has greater advantages in recovering patients' neurological function.

Objective To explore the clinical efficacy of early micro-porous surgery in the treatment of patients with encephaledema after small-and moderate-volume basal ganglia hemorrhage and its influence on serum inflammatory factors.Methods A total of 104 patients with small-and moderate-volume basal ganglia hemorrhage were randomly divided into control group and observation group,52 cases in each group.Control group was treated with conventional treatment,while observation group was treated with early micro-porous surgery.The volume of encephaledema and clearance time of hematoma 3 d and 14 d after treatment were observed in both groups.The levels of serum interleukin-6 (IL-6),IL-13 and tumor necrosis factors-α (TNF-o) were detected before treatment and 3 d after treatment in both groups.National Institutes of Health Stroke Scale (NIHSS) and Activities of Daily Life Function Assessment Scale Barthel index (BI) were used before and 3 weeks after treatment to evaluate patients' neurological function.Results The 3 d and 14 d after treatment,observation group was significantly smaller in volume of encephaledema (P ＜ 0.05) and shorter in clearance time of hematoma (P ＜0.01) when compared with control group.Three days after treatment,levels of serum IL-6,IL-1 β and TNF-α decreased significantly in both groups,which decreased more significantly in observation group than in control group (P ＜0.05 or P ＜0.01).Three weeks after treatment,NIHSS score decreased significantly while BI increased significantly in both groups,which improved more significantly in observation group than in control group (P ＜ 0.05).Conclusion Early micro-porous surgery can significantly relieve the severity of encephaledema after intracerebral hemorrhage,and has greater advantages in recovering patients' neurological function.

Objective: Hepatitis B surface antigen (HBsAg) loss is seldom achieved with nucleos(t)ide analog (NA) therapy in chronic hepatitis B patients but may be enhanced by switching to finite pegylated-interferon (Peg-IFN) alfa-2a. We assessed HBsAg loss with 48- and 96-week Peg-IFN alfa-2a in chronic hepatitis B patients with partial response to a previous NA. Methods: Hepatitis B e antigen (HBeAg)-positive patients who achieved HBeAg loss and hepatitis B virus DNA < 200 IU/mL with previous adefovir, lamivudine or entecavir treatment were randomized 1:1 to receive Peg-IFN alfa-2a for 48 (n = 153) or 96 weeks (n = 150). The primary endpoint of this study was HBsAg loss at end of treatment. The ClinicalTrials.gov identifier is NCT01464281. Results: At the end of 48 and 96 weeks' treatment, 14.4% (22/153) and 20.7% (31/150) of patients, respectively, who switched from NA to Peg-IFN alfa-2a cleared HBsAg. Rates were similar irrespective of prior NA or baseline HBeAg seroconversion. Among those who cleared HBsAg by the end of 48 and 96 weeks' treatment, 77.8% (14/18) and 71.4% (20/28), respectively, sustained HBsAg loss for a further 48 weeks. Baseline HBsAg < 1 500 IU/mL and week 24 HBsAg < 200 IU/mL were associated with the highest rates of HBsAg loss at the end of both 48- and 96-week treatment (51.4% and 58.7%, respectively). Importantly, extending treatment from 48 to 96 weeks enabled 48.3% (14/29) more patients to achieve HBsAg loss. Conclusion Patients on long-term NA who are unlikely to meet therapeutic goals can achieve high rates of HBsAg loss by switching to Peg-IFN alfa-2a. HBsAg loss rates may be improved for some patients by extending treatment from 48 to 96 weeks, although the differences in our study cohort were not statistically significant. Baseline and on-treatment HBsAg may predict HBsAg loss with Peg-IFN alfa-2a.